Perospirone is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania. Perospirone exhibits a receptor profile characterized by high affinity antagonism at serotonin 5-HT2A receptors, dopamine D2 receptor antagonism with partial agonist activity at 5-HT1A receptors, and measurable affinity for alpha1 adrenergic receptors; this mix of activities is thought to contribute to antipsychotic efficacy with a relatively lower incidence of extrapyramidal symptoms compared with typical antipsychotics. The compound is orally active, undergoes extensive hepatic biotransformation via oxidative pathways to multiple polar metabolites, and is monitored in clinical and preclinical studies by plasma concentration measurement using validated LC-MS methods to correlate exposure with clinical effects.
Typical impurity control for perospirone drug substance and formulated product targets specified related substances including N-oxide metabolites, dealkylated and despropyl derivatives, hydroxy and other oxidative metabolites, and stereoisomeric impurities; common synthetic-related impurities include residual starting materials and process-related byproducts. Industry practice and regulatory guidance generally set reporting thresholds at 0.05 percent weight by weight, identification thresholds at 0.10 percent w/w, and control limits for individual specified impurities at or below 0.10 percent w/w with total impurities maintained under 0.50 percent w/w unless justified by safety data. Analytical characterization routinely uses HPLC with UV detection, LC-MS for mass confirmation, chiral chromatography for enantiomeric assessment, NMR for structural assignment, and GC for residual solvent profiling to ensure batches meet specification.
Perospirone is used primarily for the treatment of schizophrenia and for acute manic episodes in bipolar disorder; it is prescribed to reduce psychotic symptoms such as delusions and hallucinations and to stabilize acute mood disturbance under clinical supervision.
Perospirone is marketed in Japan under the brand name Lullan.
Reported terminal elimination half life values for perospirone in healthy subjects and patients are in the range of approximately 3 to 6 hours, with pharmacodynamic effects potentially influenced by active metabolites and individual metabolic variability.
Psychostimulant medications such as amphetamine and methylphenidate increase synaptic dopamine and are used in psychiatry to treat conditions like attention deficit hyperactivity disorder; other agents that increase dopamine include certain dopamine agonists used for Parkinson disease but those are used less commonly for primary psychiatric indications.
